IDIX Related Analyst Ratings
-
Caris & Co Downgrades Idenix Pharmaceuticals (IDIX) to Above Average
-
Wedbush Assumes and Initiates Coverage on Several Key Biotech Players in Anti-Viral Space
-
JMP Downgrades Idenix Pharma (IDIX) to Market Perform
-
Thomas Weisel Initiates Coverage on Idenix Pharmaceuticals (IDIX) with an Overweight
-
Goldman Sachs Downgrades Idenix Pharmaceuticals (IDIX) to Sell
-
ThinkPanmure Initiates Coverage on Idenix Pharmaceuticals (IDIX) with an Accumulate
-
Susquehanna Upgrades Idenix Pharmaceuticals (IDIX) to Positive
-
Oppenheimer Initiates Coverage on Idenix Pharmaceuticals (IDIX) with a Perform
-
S&P Equity Research Downgrades Idenix Pharmaceuticals (IDIX) to Hold
-
Susquehanna downgrades Idenix Pharmaceuticals (IDIX) to Neutral
-
Merrill Lynch Starts Idenix Pharma (IDIX) at Neutral
-
Morgan Joseph Initiates Coverage on Idenix Pharmaceuticals (IDIX) with a Buy
-
Friedman Billings downgrades Idenix Pharmaceuticals (IDIX) to Market Perform
-
Goldman Sachs downgrades Idenix Pharma (IDIX) to Neutral
-
Piper Jaffray lowers its price target on Idenix (IDIX)
-
ThinkEquity downgrades Idenix (IDIX) to Underperform
-
Piper Jaffray Starts Idenix Pharma (IDIX) at Underperform
-
ThinkEquity Downgrades Idenix Pharmaceuticals (IDIX) to Accumulate
-
Citigroup downgrades Idenix Pharma (IDIX) to Hold
-
ThinkEquity upgrades IDIX to Buy
-
Friedman Billings Starts IDIX at Outperform
-
JP Morgan Initiates IDIX
-
Citigroup Starts IDIX at Buy
-
ThinkEquity Downgrades IDIX
-
ThinkEquity Downgraded IDIX
-
Piper Jaffray Raises Price Target on ANDS To $15
-
IDIX started at Buy at ThinkEquity
Back to IDIX Stock Lookup
